Paul Rennie

Paul Rennie, Managing Director has extensive sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialisation of Recaldent, a novel biopharmaceutical arising from research at the Melbourne Dental School, University of Melbourne. Paul took this R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently he worked in a number of positions with Mesoblast Ltd. He was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul founded Paradigm Biopharmaceuticals in early 2014 and subsequently listed the Paradigm on the Australian Stock Exchange in 2015.